AnaptysBio (NASDAQ:ANAB) Insider Paul Lizzul Sells 1,500 Shares

AnaptysBio, Inc. (NASDAQ:ANAB) insider Paul Lizzul sold 1,500 shares of AnaptysBio stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $50.00, for a total transaction of $75,000.00. Following the transaction, the insider directly owned 26,967 shares of the company’s stock, valued at approximately $1,348,350. This trade represents a 5.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

AnaptysBio Stock Down 0.6%

Shares of NASDAQ ANAB traded down $0.29 on Tuesday, reaching $50.04. 406,939 shares of the company’s stock traded hands, compared to its average volume of 692,903. The business’s 50 day simple moving average is $39.15 and its two-hundred day simple moving average is $29.22. AnaptysBio, Inc. has a 12 month low of $12.21 and a 12 month high of $51.43. The company has a market cap of $1.39 billion, a price-to-earnings ratio of -17.74 and a beta of 0.28.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.The business had revenue of $76.32 million during the quarter, compared to analysts’ expectations of $15.83 million. Analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its board has approved a share buyback plan on Friday, November 21st that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the biotechnology company to reacquire up to 9.6% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its stock is undervalued.

Analysts Set New Price Targets

A number of analysts have commented on ANAB shares. Weiss Ratings reissued a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, October 8th. Barclays dropped their price target on shares of AnaptysBio from $70.00 to $55.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. HC Wainwright reduced their price target on shares of AnaptysBio from $52.00 to $51.00 and set a “buy” rating for the company in a research note on Monday, November 24th. Wall Street Zen upgraded shares of AnaptysBio from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 16th. Finally, Truist Financial lifted their target price on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research report on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $55.40.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. First Light Asset Management LLC lifted its holdings in shares of AnaptysBio by 433.3% in the first quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock worth $86,139,000 after buying an additional 3,764,720 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in AnaptysBio by 4,852.7% during the third quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock valued at $25,719,000 after acquiring an additional 822,975 shares in the last quarter. Caption Management LLC increased its holdings in AnaptysBio by 106.3% in the 1st quarter. Caption Management LLC now owns 23,376 shares of the biotechnology company’s stock valued at $435,000 after acquiring an additional 394,634 shares during the last quarter. Woodline Partners LP lifted its stake in AnaptysBio by 63.1% in the 1st quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock worth $14,705,000 after purchasing an additional 305,950 shares in the last quarter. Finally, 683 Capital Management LLC boosted its holdings in shares of AnaptysBio by 155.6% during the 2nd quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock valued at $11,100,000 after purchasing an additional 304,373 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.